| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Berbamine — berbamine is a natural bisbenzylisoquinoline alkaloid with pleiotropic anticancer signaling activity. It is best classified as a plant-derived small-molecule natural product and investigational anticancer lead rather than an approved oncology drug. Standard abbreviation: BBM. It is chiefly isolated from Berberis species, especially Berberis amurensis, and has also been reported in other alkaloid-containing medicinal plants. The strongest mechanistic signal in cancer appears to be inhibition of CaMKIIγ-centered survival signaling, with downstream effects on c-Myc, STAT3, β-catenin, PI3K/Akt-related survival programs, apoptosis, and in some models ROS-linked stress responses. Clinical oncology translation remains limited; most evidence is preclinical, and formulation constraints have been noted because native berbamine has limited tumor-site exposure and short plasma persistence in vivo. Primary mechanisms (ranked):
Bioavailability / PK relevance: Native berbamine appears PK-limited for systemic oncology use. Multiple papers describe short plasma half-life or poor tumor-site exposure as a practical limitation, which is one reason nanoparticle and derivative strategies have been pursued. I did not find a robust modern human PK package for parent berbamine suitable for quantitative clinical extrapolation; stronger PK data were easier to find for derivatives than for the native compound. In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar in-vitro concentrations, often around 5–20 μM and sometimes higher. That makes direct translation to achievable free systemic exposure uncertain for native berbamine. Mechanistic direction is plausible, but potency-to-exposure matching remains a major translational bottleneck unless formulation or structural optimization is used. Clinical evidence status: Preclinical for cancer. Evidence includes cell culture and xenograft studies across leukemia and several solid tumors, plus medicinal-chemistry optimization work on derivatives. I did not find established randomized oncology trials or standard clinical deployment for cancer treatment. Berbamine is a bisbenzylisoquinoline alkaloid, meaning it is composed of two benzylisoquinoline moieties. Its unique structure distinguishes it from many other natural alkaloids Berbamine is most often isolated from the plant Berberis, commonly known as barberry. Various species within this genus have been used in traditional Chinese medicine and other herbal traditions. plants in genera like Stephania have also been reported to contain bisbenzylisoquinoline alkaloids like berbamine. These plants are used in various parts of Asia both for their stimulant effects and other medicinal purposes.Oxidative Stress: Berbamine can increase the production of reactive oxygen species within cancer cells. Elevated ROS levels may push cancer cells beyond their threshold of tolerance, leading to oxidative stress–induced cell death. This property also ties in with its ability to modulate apoptosis and autophagy. Berbamine is a promising natural compound with multifaceted anticancer properties. Its ability to induce apoptosis, cause cell cycle arrest, modulate key signal transduction pathways (such as JAK/STAT, NF-κB, and PI3K/Akt/mTOR), and affect autophagy, makes it a candidate for further investigation in various cancer models. A calcium channel blocker. Mechanistic relevance in cancer
P: 0–30 min |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 5553- | BBM, | A review on berbamine–a potential anticancer drug |
| - | Review, | Var, | NA |
| 5547- | BBM, | Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway |
| - | in-vitro, | CRC, | HT29 |
| 5539- | BBM, | Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway |
| - | vitro+vivo, | CRC, | SW480 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:40 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid